Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.

Pathology Oncology Research : POR
A IllésZs Molnár

Abstract

Clinicopathological features of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) differ from those of the classical Hodgkin lymphoma (cHL). Our aim was to examine clinical presentation, therapeutic and survival results of NLPHL patients in Hungary based on the data of two centres, and incidentally we analyzed the clinicopathological characteristics and differential diagnostic difficulties of this rare entity. We analyzed the clinical features, treatment and survival data of 536 Hodgkin lymphoma patients who had been diagnosed and primarily treated in our institutes between 1995 and 2004. Mean follow-up time was 82.7 (3-144) months of the total 536 HL patients. Sixteen (3%) of the patients were diagnosed with NLPHL, 93% of them presented with early-stage disease. None of the patients showed extranodal or splenic involvement or bulky disease. One patient received chemotherapy alone, six received only involved field radiotherapy while six underwent combined modality treatment. We applied watch and wait strategy in three cases. Overall response rate was 100% (93.75% complete). Two NLPHL cases transformed to non-Hodgkin's lymphoma. In contrast to the classical HL, the 10-year prognosticated overall survival rate was 100 vs. 8...Continue Reading

References

Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T A ListerM Tubiana
May 7, 1998·The Veterinary Record·P N MishraS K Panda
Feb 2, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N L Harris
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Sep 21, 2002·International Journal of Pediatric Otorhinolaryngology·John Hicks, Catherine Flaitz
Feb 15, 2003·Blood·Bradley C EkstrandSandra J Horning
Jun 27, 2003·The American Journal of Surgical Pathology·Ahmet DoganPeter G Isaacson
Jul 13, 2005·European Journal of Haematology. Supplementum·Lucia NogováAndreas Engert
Dec 7, 2005·The American Journal of Surgical Pathology·Sa A WangNancy Lee Harris
Jun 27, 2007·Seminars in Radiation Oncology·Henry K Tsai, Peter M Mauch
Oct 3, 2007·Hematology/oncology Clinics of North America·Stephan Mathas
Oct 3, 2007·Hematology/oncology Clinics of North America·Volker DiehlDaniel Re

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Current Hematologic Malignancy Reports
Michael FuchsGerman Hodgkin Study Group
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Lucia NogováGerman Hodgkin Study Group
Annals of Oncology : Official Journal of the European Society for Medical Oncology
C JacksonAndrew Wotherspoon
Annual Review of Immunology
Shane Crotty
© 2022 Meta ULC. All rights reserved